Clinical Research Directory
Browse clinical research sites, groups, and studies.
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Summary
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients. The primary outcomes are the improvement of liver inflammation or fibrosis parameters after 24 weeks treatment. The adverse events were also recorded.
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-03-11
Completion Date
2025-12-31
Last Updated
2025-03-03
Healthy Volunteers
No
Conditions
Interventions
dapagliflozin (Forxiga)
The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
Locations (1)
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
New Taipei City, Taiwan